<DOC>
	<DOC>NCT00437216</DOC>
	<brief_summary>Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.</brief_summary>
	<brief_title>Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis</brief_title>
	<detailed_description>Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents, as determined by the change in the target plaque severity (TPS) rating between Weeks 0 and 4.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Moderate to severe plaque psoriasis between 3% and 20% of Body Surface Area (BSA) with a target plaque severity (TPS) of moderate to severe At least 1 target site (not on the palms or soles of the feet) with a TPS rating of moderate to severe and with 1 or more elevated, easily palpable, plaques having wellcircumscribed margins, and at least 1 cm in diameter History of stable plaque psoriasis of greater than or equal to 3 months Diagnosis of guttate, generalized pustular, erythrodermic, psoriatic arthritis, or nail psoriasis as the sole or predominant form of psoriasis Psoriatic arthritis that was not stable or might have required a change in medication during the 4week study period Plaque psoriasis requiring treatment on the face, scalp, neck, groin, and armpits</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>